Ligand Pharmaceuticals | LGND - Ordinary Share Capital


Ligand Pharmaceuticals reported $19.66M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Agenus USD 38.52M 3.2M Mar/2026
Amgen USD 541M 1000K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 140.57M 3.18M Mar/2026
Baxter International USD 517M 549K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Enviri Corporation USD 81.45M 797K Dec/2025
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Pacira USD 39.82M 512K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 79.79M 1000 Jun/2026